George Coukos
@coukosgeorge
Obsessed about T cells, quality, truth, hard work - aiming for the cure
ID: 1432628818913734661
31-08-2021 08:58:45
53 Tweet
910 Takipçi
68 Takip Edilen
Delighted to share our paper, biorxiv.org/content/10.110… . Huge thanks to George Coukos for the opportunity as well as all our collaborators, Santiago Carmona 🧬 🖥️ 🧑🏾🔬. A summary of our main findings:
George Coukos Ludwig Cancer Oncology UNIL CHUV A summary of our main Findings 1-Orthogonal combinatorial T-cell engineering overcomes homeostatic barriers to engraftment, reprograms TILs as well as the tumor microenvironment and mediates solid tumor regression in the absence of preconditioning or systemic cytokine support.
DAY3⃣ #ASCO22 Cancer Discovery OncoAlert 🚨 FINAL5⃣papers presented by Elizabeth McKenna 🚫NO PAY WALL🧱 bit.ly/3NVxUT6 Gustave Roussy Institut Curie Katie Janeway Alberto Bardelli Fernanda G. Herrera Melita Irving Gil Morgan, MD George Coukos Oncology UNIL CHUV Ludwig Cancer CHUV / Centre hospitalier universitaire vaudois
Read also the News & Views article on the study by George Coukos, Yaquelin Ortiz-Miranda and Melita Irving: PDF: rdcu.be/c06Oa nature.com/articles/s4155…
A commentary by George Coukos, Yaquelin Ortiz-Miranda and Melita Irving -- on @UTSWNews 𝑩𝒂𝒆𝒍 𝒆𝒕 𝒂𝒍.'s study, both just out Nature Cell Biology. 📃go.nature.com/3uxhxEm Université de Lausanne CHUV / Centre hospitalier universitaire vaudois Ludwig Cancer
Another great panel discussion at #ESMOImmuno22 / Quezada Lab George Coukos Tullia Bruno, PhD Lan Coffman lab /differences between #ovarian & #fallopian tube #cancers (FT has more #TLS per Dr Coffman)/questions from Rieneke van de Ven & many more/HEV 1 marker u need 2 define TLS
TIL Therapy Entering the Mainstream pubmed.ncbi.nlm.nih.gov/36477036/ Delighted to have contributed this editorial. An important step forward for TIL therapy. Congrats to the NKI and Herlev H teams of John Haanen and Inge-Marie Svane. And a big thanks to Steve Rosenberg and colleagues!
New #JITC commentary: Patient-reported outcomes in adoptive cell-therapy trials: mind the gap bit.ly/3uFjb77 EleonoraGhisoni Matteo Morotti George Coukos Sara Colomer-Lahiguera Massimo Di Maio
Just out in Nature News & Views, George Coukos and Denarda Dangaj Laniti consider how data that reveal cellular, molecular and mutational landscape, as ovarian cancer tumours grow and spread, might aid efforts to develop new targeted therapies. Université de Lausanne @chuv Ludwig Cancer
As we ring out 2022, we wish a very happy holiday season & New Year to all our partners, supporters and followers of the academic #CancerResearch community Université de Lausanne CHUV / Centre hospitalier universitaire vaudois Ludwig Cancer.
George Coukos and colleagues show that orthogonal cytokine engineering can reprogram CD8 T cells to escape exhaustion leading to tumor regression. Read it here: rdcu.be/daodw Jesus Corria-Osorio George Coukos nature.com/articles/s4159…
Big congratulation to Doug Hanahan who has been elected as a member of the Royal Society. This is a great recognition for his outstanding contribution to cancer research! We are lucky of having him at ISREC@EPFL EPFL Life Sciences
May is National Cancer Research Month. George Coukos, MD, PhD, a Fellow of the AACR Academy, is one of the 54,000 AACR members who is Bringing Cancer Research to Life. #NCRM23 #ResearchSavesLives #AACRFellows George Coukos
Had a great time meeting all the colleagues and friends at Gustave Roussy! Thanks for the great day!